4d Molecular Therapeutics Inc share price logo

4d Molecular Therapeutics Inc Share Price

NASDAQ: FDMT

Small Cap

$8.98

+0.25

(+2.86%)

Live

as on

4d Molecular Therapeutics Inc Stock Performance

as on March 11, 2026 at 2:06 am IST

  • Day's Low

    Day's High

    $8.86
    $9.28
    downward going graph

    1.34%

    Downside

    3.34%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $2.24
    $12.34
    downward going graph

    75.11%

    Downside

    37.42%

    Upside

    downward going graph

4d Molecular Therapeutics Inc share price movements today

Previous Close
$8.73
Open
$8.88
Volume
283.0K
Day's Low - High
$8.86 - $9.28
52 Week Low - High
$2.24 - $12.34

4d Molecular Therapeutics Inc Historical Returns

1 Month Return
-4.07 %
3 Month Return
-19.39 %
1 Year Return
+ 124.13 %
3 Year Return
-43.5 %
5 Year Return
-83.01 %

4d Molecular Therapeutics Inc Stock Fundamentals & Key Indicators

Check 4d Molecular Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$484.5M

EPS (TTM)

-3.2586

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-7.21

Industry PE ratio

-3.0981227436823104

PEG Ratio

0

EBITDA

-222.7M

Revenue (TTM)

120.0K

Profit Margin

0.00%

Return On Equity TTM

-45.38%

4d Molecular Therapeutics Inc Stock Valuation

Track how 4d Molecular Therapeutics Inc P/E has moved over time to understand its valuation trends.

4d Molecular Therapeutics Inc in the last 5 years

  • Overview

  • Trends

Lowest (-11.00x)

June 30, 2024

Today (-7.21x)

March 10, 2026

Industry (-3.10x)

March 10, 2026

Highest (-1.00x)

June 30, 2025

LowHigh

Today’s Price to Earnings Ratio: -7.21x

4d Molecular Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of 4d Molecular Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
4d Molecular Therapeutics Inc image
4d Molecular Therapeutics Inc
BUY$484.5M-83.01%-7.210.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$42.5B140.27%137.038.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$116.0B115.07%29.8532.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$33.3BNA590.435.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$80.3B67.03%18.3131.41%

Stock Returns calculator for 4d Molecular Therapeutics Inc Stock including INR - Dollar returns

The 4d Molecular Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

4d Molecular Therapeutics Inc investment value today

Current value as on today

₹2,35,449

Returns

₹1,35,449

(+135.45%)

Returns from 4d Molecular Therapeutics Inc Stock

₹1,30,256 (+130.26%)

Dollar Returns*

₹5,192 (+5.19%)

Analyst Recommendation on 4d Molecular Therapeutics Inc Stock

Based on 17 analysts

BUY

94.12%

Buy

5.88%

Hold

0.00%

Sell

Based on 17 analysts, 94.12% of analysts recommend a 'BUY' rating for 4d Molecular Therapeutics Inc. Average target price of $33.11

4d Molecular Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on 4d Molecular Therapeutics Inc.

What analysts predicted

72.88%UPSIDE

Target Price

$33.11

Current Price

$8.98

Analyzed by

17 Analysts

Target

$33.11

4d Molecular Therapeutics Inc target price $33.11, a slight upside of 72.88% compared to current price of $8.98. According to 17 analysts rating.

4d Molecular Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for 4d Molecular Therapeutics Inc Stock has increased by 29% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:29% versus previous 30 day period

4d Molecular Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Total Revenue
0
20
0
0
0
0
0
0
0
0
Gross Profit
-23
-4
-26
-27
-31
0
-1
0
-47
-47
Operating Income
-32
-13
-36
-38
-42
-51
-56
-53
-59
-61
EBITDA
-31
-12
-35
-36
-41
-49
-61
-51
-58
-55
Interest Expense
-
-
1
-
-
-
-
-
-
-
Depreciation
1
1
1
1
1
1
1
1
1
2
Income Before Tax
-29
-10
-32
-32
-34
-43
-49
-47
-54
-56
Income Tax Expense
-1
-3
6
0
-
-
0
-
-
-
Net Income
-29
-10
-32
-32
-34
-43
-49
-47
-54
-56
Net Profit Margin
-12391.63%
-50.76%
169910.53%
-115717.86%
-699060.00%
-1461433.33%
-4967100.00%
-342657.14%
-364386.67%
-63195.56%

4d Molecular Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
5
14
6
13
18
3
20
0
Gross Profit
-7
-4
-31
-39
18
3
-76
0
Operating Income
-11
-10
-50
-56
-71
-110
-112
-187
EBITDA
-10
-9
-44
-55
-68
-106
-108
-181
Interest Expense
-
-
-
0
3
6
-
-
Depreciation
0
0
1
1
3
3
5
6
Income Before Tax
-11
-9
-49
-56
-71
-107
-100
-160
Income Tax Expense
0
0
3
0
-3
-6
5
-
Net Income
-11
-9
-49
-56
-68
-101
-100
-160
Net Profit Margin
-193.83%
-67.59%
-705.78%
-416.49%
-378.63%
-3230.30%
-486.59%
-434778.38%

4d Molecular Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Net Income
-10
-32
-32
-34
-43
-49
-47
-54
-56
Operating Cash Flow
-1
-24
-29
-30
-29
-45
-47
-43
-46
Investing Cash Flow
29
-6
-263
-73
27
7
31
-13
17
Financing Cash Flow
10
4
318
17
0
0
-
0
0
Change in Cash
39
-26
26
-86
-1
-38
-15
-63
-28

4d Molecular Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-9
-49
-56
-71
-107
-100
-160
Operating Cash Flow
-16
-36
-50
-69
-86
-75
-134
Investing Cash Flow
0
-3
-1
-172
-17
115
-302
Financing Cash Flow
84
-2
278
118
3
156
337
Change in Cash
67
-42
227
-123
-100
196
-99

Global Institutional Holdings in 4d Molecular Therapeutics Inc

Funds
Holdings
Susquehanna International Group, LLP
0.26%
Novo A/S
7.16%
Vanguard Group Inc
5.86%
State Street Corp
2.06%
Millennium Management LLC
2.25%
See all

Insights on 4d Molecular Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, FDMT stock has moved up by 124.1%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 1.0K → 90.0K (in $), with an average increase of 61.0% per quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, FDMT has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 77.2% return, outperforming this stock by 120.7%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, -47.97M → -56.87M (in $), with an average decrease of 9.0% per quarter

About 4d Molecular Therapeutics Inc

the mission of 4d molecular therapeutics is to design and develop transformative gene therapy products using our proprietary technology to create novel adeno-associated virus variants to be utilized as treatments for serious unmet medical conditions. our products are unlocking the full potential of gene therapy to treat, and potentially cure, genetic diseases. a large number of patients and diseases, who previously were not treatable by gene therapy, will be addressable by 4d products. 4d has one of the deepest and most diverse product pipelines in the gene therapy field. adeno-associated virus (aav) vectors have emerged as a favored delivery vehicle for gene therapy in the human body. they can deliver the genes for therapeutic proteins to accessible tissues in the body and are generally considered safe. several aav gene therapy products are in late-stage clinical development, and one product is approved in the eu (glybera, uniqure). however, these first-generation aav vectors have lim
Organisation4d Molecular Therapeutics Inc
Headquarters5858 Horton Street, EmeryVille, CA, United States, 94608
IndustryHealthcare
CEODr. David H. Kirn M.D.
E-voting on sharesClick here to vote

Key Management of 4d Molecular Therapeutics Inc

Name

Title

Dr. John F. Milligan Ph.D.

Executive Chairman

Julian Pei

Head of Investor Relations & Corporate Finance

Dr. Katy Barglow Ph.D.

Chief Technical Officer

Mr. Kristian Humer M.B.A.

CFO & Principal Financial Officer

Mr. Ashoo Gupta

Principal Accounting Officer & Principal Financial Officer

Dr. Scott P. Bizily J.D., Ph.D.

Chief Legal Officer & Corporate Secretary

Dr. An Song Ph.D.

Chief Translational Medicine Advisor

Dr. David H. Kirn M.D.

Co-Founder, President, CEO & Director

Dr. Fariborz Kamal Ph.D.

Chief Technical Advisor

Ms. Theresa Janke

Co-Founder & Chief of Staff

FAQs

What is 4d Molecular Therapeutics Inc share price today?

4d Molecular Therapeutics Inc share price today is $8.98 as on . 4d Molecular Therapeutics Inc share today touched a day high of $9.28 and a low of $8.86.

What is the 52 week high and 52 week low for 4d Molecular Therapeutics Inc share?

4d Molecular Therapeutics Inc share touched a 52 week high of $12.34 on and a 52 week low of $2.24 on . 4d Molecular Therapeutics Inc stock price today i.e. is trending at $8.98,which is 27.23% down from its 52 week high and 301.79% up from its 52 week low.

What is 4d Molecular Therapeutics Inc's market capitalisation today?

4d Molecular Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in 4d Molecular Therapeutics Inc Stock (FDMT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for 4d Molecular Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in 4d Molecular Therapeutics Inc Shares that will get you 0.1670 shares as per 4d Molecular Therapeutics Inc share price of $8.98 per share as on March 10, 2026 at 8:36 pm IST.

What is the minimum amount required to buy 4d Molecular Therapeutics Inc Stock (FDMT) from India?

Indian investors can start investing in 4d Molecular Therapeutics Inc (FDMT) shares with as little as ₹91.833 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹918.33 in 4d Molecular Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on 4d Molecular Therapeutics Inc share’s latest price of $8.98 as on March 10, 2026 at 8:36 pm IST, you will get 1.1136 shares of 4d Molecular Therapeutics Inc. Learn more about fractional shares .

What are the returns that 4d Molecular Therapeutics Inc has given to Indian investors in the last 5 years?

4d Molecular Therapeutics Inc stock has given -83.01% share price returns and 26.32% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?